Esperion Settled Patent Dispute With Renata Limited

The agreement prevents Renata from launching generic versions of NEXLETOL and NEXLIZET until 2040.

Updated on Oct. 7, 2026 in Healthcare

Isometric editorial illustration showing a row of three clean pharmaceutical containers on a lab bench, representing long-term market protection. — Esperion Therapeutics has reached a settlement with Renata Limited, securing market exclusivity for its cardiovascular drugs NEXLETOL and NEXLIZET until 2040. AI Illustration. Upload story photo >

Live Poll

Do you believe patent settlements that delay cheaper generic drugs are good for your household budget?

Ann Arbor-based Esperion has reached a settlement agreement with Renata Limited to resolve patent litigation. The deal blocks the marketing of generic versions of the company’s drugs, NEXLETOL and NEXLIZET, until April 19, 2040.

Why it matters

This settlement provides legal certainty for Esperion by delaying competition from a generic manufacturer for its core cardiovascular products. It effectively protects the company's intellectual property rights and market exclusivity in the United States for over a decade.

Renata Limited is prohibited from marketing generic versions of NEXLETOL and NEXLIZET in the U.S. until April 19, 2040. Litigation regarding these products currently continues against other manufacturers.

The players

Esperion

Headquartered in Ann Arbor, Michigan, this pharmaceutical company specializes in the development of therapies for cardiovascular and metabolic diseases.

Renata Limited

This pharmaceutical manufacturer produces various medical products and faced litigation over its applications to market generic versions of existing drugs.

Aurobindo Pharma Limited

This global pharmaceutical firm is currently involved in ongoing patent litigation with Esperion.

MSN Pharmaceuticals Inc.

This company develops and manufactures generic pharmaceutical products and remains a defendant in active patent litigation.

Sandoz Inc.

A major player in the global generics market, this company is also currently engaged in patent litigation with Esperion.

The details

Esperion initiated patent litigation after Renata Limited filed Abbreviated New Drug Applications seeking to bring generic versions of the drugs to market. While this dispute is resolved, legal battles against Aurobindo Pharma Limited, MSN Pharmaceuticals Inc., and Sandoz Inc. remain ongoing.

October 7, 2026: The settlement agreement was announced.
April 19, 2040: The earliest date Renata may market generic versions.

Market Landscape

The settlement follows the established negotiation patterns dictated by the Hatch-Waxman Act's patent litigation framework. This move helps Esperion maintain its competitive positioning in the cardiovascular drug sector while other manufacturer challenges persist.

Patients currently relying on NEXLETOL and NEXLIZET should expect no changes to their treatment availability or costs as a result of this specific settlement. The drug remains branded and protected, preventing lower-cost generic alternatives from entering the market until at least 2040.

The takeaway

This settlement underscores the complexity of protecting pharmaceutical intellectual property as generic companies push for earlier market access. Investors and patients should monitor the ongoing litigation with other manufacturers, which may still alter the future availability of lower-cost generic versions.